CITIUS ONCOLOGY, INC. Stockholders Equity

Quick Answer

CITIUS ONCOLOGY, INC. reported Stockholders Equity of $44.87 million for fiscal year 2025.

CITIUS ONCOLOGY, INC. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $44.87M -2.8%
2024 $46.14M +2421.5%
2023 -$1.99M -107.8%
2023 $25.54M +7290.8%
2022 $345.5K -99.0%
2022 $36.27M +358721.6%
2021 -$10.1K

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
December 31, 2025 $58.41M +41.5% +30.2%
September 30, 2025 $44.87M -2.8% +38.5%
June 30, 2025 $32.40M +90.2% -9.1%
March 31, 2025 $35.64M +79.6% -13.7%
December 31, 2024 $41.29M +81.7% -10.5%
September 30, 2024 $46.14M +80.7% +170.9%
June 30, 2024 $17.03M +865489.3% -14.2%
March 31, 2024 $19.85M +9944.6% -12.7%
  • CITIUS ONCOLOGY, INC. showed a decrease of -2.8% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2021–2025 period, CITIUS ONCOLOGY, INC.’s stockholders equity has grown by 443749.1% (from -$10.1 thousand to $44.87 million).
  • The most recent figure is from CITIUS ONCOLOGY, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 23, 2025.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment